Lonza Group broke ground at Tuas Biomedical Park in Singapore for the new facility for its Cell Therapy business. The new facility will be adjacent to the company’s large-scale mammalian manufacturing facility. Stefan Borgas, chief executive officer of Lonza, said, “This new Cell Therapy manufacturing facility is a next step in fulfilling our strategy to expand our capacity globally and our presence in Asia. Cell Therapy is expected to be one of the most important innovation drivers of modern...